Fib-mAb (Crucell)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameFib-mAb (Crucell)
Drug Alias Nameanti-fibronectin mAb (Crucell)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAngiogenesis modulatorsIntegrin beta-1 inhibitors
TargetsIntegrin beta-1
Therapy Area/IndicationsSolid tumoursAngiogenesis disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrucell NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrucell NV
Active IndicationsN/A
Inactive IndicationsSolid tumoursAngiogenesis disorder

Other Information

ATC CodeN/A
Related LinksN/A